

Interface and Formulary Update - Issue 41

March 2026

Key messages from March 2026 TAG meeting - (ratified by Medicines Optimisation Programme Board)

Formulary Review – Catheter Valves and Adhesive Removers

- Netformulary and relevant guidance documents to be updated with information on catheter valves and adhesive removers that have **BLACK** classifications and so should not be prescribed

Formulary Review – Trifarotene (Aklief®) cream for acne

- **AMBER ADVICE**
- Second line after Adapalene where combination treatment isn't appropriate

Formulary Review – Ticagrelor for treatment of Transient Ischaemic Attack (TIA) or minor stroke in patients with Clopidogrel allergy or suspected Clopidogrel resistance, in combination with low dose aspirin, followed by secondary prophylaxis if applicable

- **AMBER INITIATE**
- Specialist will be responsible for the first prescription. They should provide the initial supply (at least 14 days) and include full details about primary care continuation and duration on the discharge / clinic letter
- Gastro protection should be prescribed when Ticagrelor treatment is combined with Aspirin

Formulary Review – Aflibercept 8mg preparation as per Medical Retinal Treatment Pathway in Wet Age-Related Macular Degeneration

- **RED HOSPITAL ONLY**
- Second-line option after Ranibizumab and Aflibercept 2mg

Shared Care Review – Denosumab for treatment of osteoporosis in post-menopausal women at increased risk of fracture

- Added use in men and changed title to '**Denosumab for prevention of osteoporotic fractures in men and post-menopausal women**'
- Amended to a **Level 1** agreement due to the requirement for 6-monthly monitoring
- Removed references to branded 'Prolia®'. Biosimilar now available

Formulary Updates

Drug-Induced Extrapyrimal Side Effects

- **Procyclidine** added as a first-line option, with **Trihexphenidyl** (formerly known as benzhexol) as alternative
- **Orphenadrine** and **Benztpine** added to non-formulary section as per NSFT formulary

Inhaler formulary update

- Addition of **Proxor®** as a cost-effective option for new patients
- **Luforbec®** moved to non-formulary, except for existing patients
- Note – these inhalers are only licensed for adults, with dry powder inhalers remaining preferred option due to lower carbon

Traffic Light Additions / Updates (to be read in conjunction with [TAG Agreement document](#))

RED	TA1119 – January 2026 - Venetoclax (Venclyxto®) with obinutuzumab for untreated chronic lymphocytic leukaemia (replaces TA663)
	TA1120 – January 2026 - Avelumab (Bavencio®) with axitinib for untreated advanced renal cell carcinoma (replaces TA645)
	TA1121 – January 2026 - Acoramidis (Beyontra®) for treating transthyretin amyloidosis with cardiomyopathy
	TA1122 – January 2026 - Amivantamab (Rybrevant®) with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer
	TA1128 – February 2026 - Targeted-release budesonide for treating primary IgA nephropathy (replaces TA937)
	TA1126 – January 2026 - Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy
	TA1127 – February 2026 - Nivolumab (Opdivo®) with chemotherapy for neoadjuvant treatment then alone for adjuvant treatment of resectable non-small-cell lung cancer
	TA1129 – February 2026 - Niraparib (Zejula®) for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy – (replaces TA673)
	TA1130 – February 2026 - Talazoparib (Talzenna®) with enzalutamide for untreated hormone-relapsed metastatic prostate cancer
	TA1131 – February 2026 - Obinutuzumab (Gazyvaro®) with mycophenolate mofetil for treating lupus nephritis
	TA1133 – February 2026 - Belantamab mafodotin (Blenrep®) with pomalidomide and dexamethasone for previously treated multiple myeloma
	TA1136 – February 2026 - Bevacizumab (originator and biosimilars) with fluoropyrimidine-based chemotherapy for metastatic colorectal cancer – (replaces TA212 and partially replaces TA242 and TA118)
	TA1134 – February 2026 - Dupilumab (Dupixent®) for treating severe chronic rhinosinusitis with nasal polyps – (replaces TA648)
BLACK	TA1118 – January 2026 - Entrectinib for treating NTRK fusion-positive solid tumours in people 12 years and over
	TA1123 – January 2026 - Depemokimab for treating chronic rhinosinusitis with nasal polyps in adults
	TA972 – May 2024, updated January 2026 - Sirolimus (Hyftor®) for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over
	TA1124 – January 2026 - Concizumab for treating haemophilia A or B in people 12 years and over with factor inhibitors
	TA1125 – January 2026 - Pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated unresectable advanced malignant pleural mesothelioma
	TA878 – March 2023, updated February 2026 - Nirmatrelvir plus ritonavir and tocilizumab for treating COVID-19
	TA1056 – April 2025, updated February 2026 - Molnupiravir for treating COVID-19 Sotrovimab to be removed from formulary and given BLACK classification
	HST34 – February 2026 - Cerliponase alfa (Brineura®) for treating neuronal ceroid lipofuscinosis type 2 – (replaces HST12). Amend from RED to BLACK
	TA1132 – February 2026 - Ruxolitinib for treating moderate to severe chronic graft versus host disease after an allogeneic stem cell transplant in people 28 days to 17 years
	TA1135 – February 2026 - Baloxavir marboxil for treating and preventing influenza in children 1 to 11 years
	TA1137 – February 2026 - Canagliflozin for treating type 2 diabetes in people 10 to 17 years

Prescribing Guidance Updates

- Primary Care Diagnosis & Management of **Vitamin D Deficiency in Children**
- Guidance for prescribing **emollients** containing antiseptics e.g. Dermol
- **Emollient** pathway
- **Compression Hosiery** formulary update
- SOP15 – **Thickener** Ordering
- Guideline for prescribing **oral nutritional supplements** for adults in primary care
- **Infant Feeds** formulary
- **Nutritional Guidance** for Care Homes
- **Continence** formulary

Useful Information

Next TAG meeting	TBC
Deadline for agenda items	TBC
Netformulary	Norfolk and Waveney Formulary (norfolkandwaveneyformulary.nhs.uk)
Knowledge NoW – MO Team pages	Prescribing, Pharmacy and Medicines Optimisation - Knowledge NoW (nwknowledgenow.nhs.uk)
TAG Guidance	Therapeutic Advisory Group (TAG) and Commissioning - Knowledge NoW (nwknowledgenow.nhs.uk)
Shared Care Agreements	Shared Care Agreements - Knowledge NoW (nwknowledgenow.nhs.uk)
Pathways and Prescribing Guidance	Pathways and Prescribing Guidance - Knowledge NoW (nwknowledgenow.nhs.uk)
Practice Support	Practice Support - Knowledge NoW (nwknowledgenow.nhs.uk)
Useful Links	Useful Links - Knowledge NoW (nwknowledgenow.nhs.uk)

- **Please remember to check both [KNoW](#) and [Netformulary](#) for regular formulary updates**
- If you have any interface or formulary queries, please send to the inbox - nwicb.medsqueries@nhs.net